Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions
Over half of refractory AML patients responded to combo
Advani A et al. ASH 2017, Abstract 150.
Key clinical point:
Major finding: The overall response rate was 53%.
Study details: A phase 1 trial involving 30 patients.
Disclosures: Dr. Advani reported receiving research funding from Takeda/Millenium, and serving as a consultant for Pfizer.
Source: Advani A et al. ASH 2017, Abstract 150.
Citation:
Advani A et al. ASH 2017, Abstract 150.